If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: GCP Infra hails NAV rise; Jadestone profits from oil

Fri, 03rd Feb 2023 15:17

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

4D Pharma PLC - Leeds-based pharmaceutical firm - Gives update on signal finding study of MRx0518 in combination with anti-PD-1 therapy Keytruda on patients with solid tumours that have progressed on a prior immune checkpoint inhibitor. In March, the company noted four patients with renal cell carcinoma, which had experienced durable stable disease. Renal cell carcinoma is a cancer of cells in the lining of tubules in the kidney. On Thursday, 4d Pharma says one of the four patients is partially responding to the treatment with MRx0518 in combination with anti-PD-1 therapy Keytruda. "Despite recent setbacks in the microbiome field experienced by other companies and the limitations on patient recruitment as a result of the administration, we are delighted that patients continue to benefit from the trial treatment. We continue to build on the body of evidence for the future development of MRx0518 and 4D's approach to Live Biotherapeutics," says Alex Stevenson, chief scientific officer at 4D pharma.

----------

Darktrace PLC - Cambridge, England-based cybersecurity business - Chief Executive Officer Poppy Gustafsson buys 48,000 shares for GBP2.254 each, worth GBP108,192.

----------

GCP Infrastructure Investments Ltd - Jersey, UK-based investment fund focused on UK infrastructure projects - Net asset value as at December 31 rises 6.0% to 113.59 pence per share from 107.18p a year prior. Says company was exposed to diversified and partially inflation protected portfolio with of 48 investments, up from 47 a year prior, with a valuation of GBP1.1 billion, unchanged. Like a year ago, the company's portfolio has a weight-adjusted average annualised yield of 7.9%. Says that it made five investments in the quarter to December 31, totalling GBP54.6 million, up from three investments totalling GBP52.8 million a year earlier.

----------

Greatland Gold PLC - London-headquartered mining development and exploration company, focused primarily on precious and base metal mining in Western Australia and Tasmania - Identifies bismuth in Western Australia at Juri joint venture, of which it owns 49% and Newcrest Mining Ltd 51%. Bismuth is a gold-copper mineralisation pathfinder element. Intersects 4 metres at 0.4 grams of gold per tonne at Black Hills hole, and 6 metres at 0.2 grams of gold per tonne at Black Hills hole. Notes that exploration confirms merit of follow-up drilling. Greatland Gold Managing Director Shaun Day says: "We are strongly encouraged by the results of our second drilling campaign at the Juri joint venture. The importance of bismuth as a pathfinder in the Paterson region is particularly significant with geochemistry at Black Hills similar to what we have seen at Havieron."

----------

Henderson Opportunities Trust PLC - Invests in the Asia Pacific region - Net asset value per share at October 31 falls 28% to 1,173.7p from 1,626.9p a year prior. NAV total return is negative 26%, including dividends reinvested, underperforming against its benchmark, which posts a negative return of 2.8%. Declares annual 34.0p per share dividend, up 24% from 27.5p a year prior. Looking ahead, says it is able to grow "substantially" despite a wider backdrop, with Chair Wendy Colquhoun noting that "this portfolio should not be seen as a proxy for the UK economy."

----------

Jadestone Energy PLC - Asia Pacific-focused oil and gas company - Says 2022 production averages 11,487 barrels of oil equivalent per day, down 8.4% from 12,545 a year ago. Company realises average oil price of USD103.93 per barrel in 2022, jumping 40% from USD74.34 a year ago. Revenue of about USD421 million is up 24% from USD340 million in 2021. Expects lifting of 4.0 million barrels of oil, down 13% from 4.6 million in 2021. Expects lifting of gas to triple in 2022 to 1.8 million cubic feet from 600,000 in 2021. In 2022, capital expenditure was about USD87 million, below the guidance of USD90 million to USD105 million but 55% higher than USD56.0 million in 2021. Looking into 2023, CEO Paul Blakeley says: "We are engaged in several mergers & acquisitions processes at present, and I am optimistic that we will be successful in resuming our growth trajectory in 2023, while remaining very disciplined about the opportunities we pursue."

----------

Mineral & Financial Investments Ltd - Cayman Island-based investor in the natural resources sector - Notes that Redcorp Empreedimentos Mineiros Lda finds 3.9% copper equivalent at Venda Nova South Zone in south Portugal. In addition, Mineral & Financial Chief Executive Officer Jacques Vaillancourt says: "We are encouraged by the confirmation that South Zone also appears to hold copper dominated mineralization similar to what we are seeing at depth in the North Zone. Additional drilling in the future is expected to expand on these discoveries."

----------

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
16 May 2019 09:59

4d Pharma To Present Data From Thetanix Clinical Study In San Diego

LONDON (Alliance News) - 4d Pharma PLC on Thursday said it will present the data from the completed phase Ib clinical study of Thetanix for the treatment of Crohn's disease on Saturday in San

Read more
29 Apr 2019 09:20

4d Pharma "Delighted" With Progress Being Made On Oncology Programme

LONDON (Alliance News) - 4d Pharma PLC on Monday reported a positive initial phase of one drug trial and the start of another.In a phase I/II trial of pembrolizumab, or Keytruda, the first

Read more
14 Mar 2019 09:53

DIRECTOR DEALINGS: 4D Pharma CEO And Chief Scientific Officer Buy

LONDON (Alliance News) - 4D Pharma PLC on Thursday said Chief Scientific Officer Alex Stevenson purchased 24,896 shares at a price of 91.5 pence each on Wednesday for a total of in 4D Pharma were

Read more
13 Mar 2019 15:36

DIRECTOR DEALINGS: 4d Pharma Non-Exec Chair And Director Buy Shares

LONDON (Alliance News) - 4d Pharma PLC on Wednesday said Non-Executive Chair David Norwood and Non-Executive Director Thomas Engelen both purchased shares in the AIM-listed pharmaceutical separate

Read more
29 Jan 2019 09:26

4D Pharma Reports Reveals MRx0518 Immune System Stimulatory Effect

LONDON (Alliance News) - 4D Pharma PLC said Tuesday tests have shown its MRx0518 cancer treatment has "strong immuno-stimulatory effects".Researchers at 4D demonstrated that - on

Read more
8 Jan 2019 10:57

4D Pharma Appoints Two Non-Executives From Xencor And Celgene

LONDON (Alliance News) - 4D Pharma PLC said Tuesday it has appointed two new independent non-executive directors, one a previous chief business officer at Xencor Inc and the other a former senior

Read more
7 Jan 2019 08:20

4d Pharma buoyed by Texas cancer treatment partnership

(Sharecast News) - 4d Pharma's shares enjoyed a boost on Monday after entering a collaboration with a specialist cancer unit at the University of Texas.

Read more
7 Jan 2019 07:57

4D Pharma Partners With Cancer Center For Cancer Treatment

LONDON (Alliance News) - 4D Pharma PLC on Monday said it has partnered with the University of Texas MD Anderson Cancer Center to evaluate its live biotherapeutic oncology pipeline.The will

Read more
12 Dec 2018 09:19

4d Pharma "Not Aware Of Matter" Responsible For Drop In Share Price

LONDON (Alliance News) - 4d Pharma PLC on Wednesday noted a recent fall in its share price, but said is not aware of any company-related reasons for the drop.The pharmaceutical company that

Read more
28 Sep 2018 10:41

4d Pharma Interim Loss Holds Steady Despite Rise In R&D Spending

LONDON (Alliance News) - 4d Pharma PLC on Friday said its loss widened only marginally in the first half of the year, despite significantly higher expenses, due to the absence of a non-recurring a

Read more
28 Sep 2018 08:29

4d Pharma losses little changed as trials begin

(Sharecast News) - First-half losses grew slightly at live biotherapeutics developer 4d Pharma as first-half research and development expenses jumped ahead of two of its major treatment candidates receiving clearance for clinical trials.

Read more
24 Sep 2018 14:19

Positive top-line results for 4D Pharma's Thetanix

(Sharecast News) - Biotherapeutics company 4D Pharma announced positive top-line results for its Phase 1b study of 'Thetanix' in paediatric patients with Crohn's disease on Monday.

Read more
24 Sep 2018 08:45

4d Pharma Reports Positive Results From Phase Ib Study Of Thetanix

LONDON (Alliance News) - 4d Pharma PLC on Monday said its phase Ib study of Thetanix in paediatric patients with Crohn's disease achieved its primary objective.Crohn's disease is a

Read more
12 Jun 2018 17:55

Janus Henderson Increases Stake In 4d Pharma To 5.2% (ALLISS)

LONDON (Alliance News) - 4d Pharma PLC said Janus Henderson Group PLC increased stake in the pharmaceutical company to 5.2% after a transaction on Tuesday.Janus Henderson raised its holding

Read more
21 May 2018 07:40

LONDON MARKET PRE-OPEN: FTSE 100 Set For All-Time Record At Open

LONDON (Alliance News) - The FTSE 100 is set to open at an all-time high on Monday, coming after trade tensions between the US and China eased over the weekend.In early UK company news on said the US

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.